Top Stories
Top Stories

UPDATE 2-Eli Lilly misses estimates for diabetes drug Trulicity, cuts revenue forecast

forecast@ (Adds details, Updates shares)

April 30 (Reuters) - Eli Lilly and Co reported lower-than-expected sales for its top-selling diabetes drug Trulicity and cut its full-year revenue forecast as it sees further hits from price declines in the United States, sending its shares down 3 percent.

The company also cited a number of challenges for the year including increased generic competition for drugs such as erectile dysfunction treatment Cialis and the global withdrawal of its cancer drug Lartruvo.

Under intensifying pressure from lawmakers to lower drug prices, Lilly agreed to offer a half-priced version of insulin injection Humalog earlier this year. The drugmaker is one of the three main global providers of insulin products.

Lilly said it now expects 2019 revenue to come in between $22.0 billion and $22.5 billion, lower than its prior forecast of $25.1 billion to $25.6 billion. Analysts had expected $22.17 billion.

Trulicity brought in $879.7 million in the first quarter, missing the average analyst estimate of $952 million, partly hurt by lower realized prices and changes in estimates to rebates and discounts in the United States.

Sales of psoriasis treatment Taltz, considered one of Lilly's growth drivers, came in at $252.5 million, also falling short of analysts' estimates.

"The results will ... lead to some pressure on Lilly shares today given the underperformance of Trulicity and Taltz," said Credit Suisse analyst Vamil Divan.

Sales of Cialis dropped 38 percent to $308.2 million as the drug continues to suffer from increased generic competition.

Net income more than tripled to $4.24 billion, or $4.31 per share, in the quarter ended March 31, as the company benefited from a $3.7 billion gain from its spin-off of animal health unit Elanco.

Excluding items, the company earned $1.33 per share, beating the average estimate of $1.31, according to IBES data from Refinitiv.

Revenue rose to $5.09 billion, but missed estimates of $5.13 billion due to lower realized prices.

The company raised its adjusted earnings forecast to $5.60 to $5.70 per share from a prior range of $5.55 to $5.65, beating the average analyst estimate of $5.63. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli and Saumyadeb Chakrabarty)